Daiken Medical Co., Ltd.

As of March 31, 2026, Daiken Medical Co., Ltd. carries a market capitalization of 12.87B, placing it among publicly traded companies globally. Its enterprise value stands at 12.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Daiken Medical Co., Ltd.'s next confirmed earnings release is scheduled for October 30, 2026.

As of March 31, 2026, Daiken Medical Co., Ltd. has 28.73M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Daiken Medical Co., Ltd. maintains a current ratio of 2.58, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Daiken Medical Co., Ltd.'s stock has declined approximately 5.97% over the past 52 weeks. The 50-day moving average sits at 424.88, while the 200-day moving average is 440.51.

As of March 31, 2026, Daiken Medical Co., Ltd. holds 2.78B in cash and equivalents against 2.25B in total debt, resulting in a net debt position of -548.32M. Total book value stands at 7.78B, with working capital of 4.31B providing operational flexibility.

Daiken Medical Co., Ltd.'s most recent stock split took place on November 13, 2014 with a 1:2 split ratio.